Literature DB >> 11434981

Signaling and gene expression in the neuron-glia unit during brain function and dysfunction: Holger Hydén in memoriam.

L Hertz1, E Hansson, L Rönnbäck.   

Abstract

Holger Hydén demonstrated almost 40 years ago that learning changes the base composition of nuclear RNA, i.e. induces an alteration in gene expression. An equally revolutionary observation at that time was that a base change occurred in both neurons and glia. From these findings, Holger Hydén concluded that establishment of memory is correlated with protein synthesis, and he demonstrated de novo synthesis of several high-molecular protein species after learning. Moreover, the protein, S-100, which is mainly found in glial cells, was increased during learning, and antibodies towards this protein inhibited memory consolidation. S-100 belongs to a family of Ca(2+)-binding proteins, and Holger Hydén at an early point realized the huge importance of Ca(2+) in brain function. He established that glial cells show more marked and earlier changes in RNA composition in Parkinson's disease than neurons. Holger Hydén also had the vision and courage to suggest that "mental diseases could as well be thought to depend upon a disturbance of processes in glia cells as in the nerve cells", and he showed that antidepressant drugs cause profound changes in glial RNA. The importance of Holger Hydén's findings and visions can only now be fully appreciated. His visionary concepts of the involvement of glia in neurological and mental illness, of learning being associated with changes in gene expression, and of the functional importance of Ca(2+)-binding proteins and Ca(2+) are presently being confirmed and expanded by others. This review briefly summarizes highlights of Holger Hydén's work in these areas, followed by a discussion of recent research, confirming his findings and expanding his visions. This includes strong evidence that glial dysfunction is involved in the development of Parkinson's disease, that drugs effective in mood disorders alter gene expression and exert profound effects on astrocytes, and that neuronal-astrocytic interactions in glutamate signaling, NO synthesis, Ca(2+) signaling, beta-adrenergic activity, second messenger production, protein kinase activities, and transcription factor phosphorylation control the highly programmed events that carry the memory trace through the initial, signal-mediated short-term and intermediate memory stages to protein synthesis-dependent long-term memory.

Entities:  

Mesh:

Year:  2001        PMID: 11434981     DOI: 10.1016/s0197-0186(01)00017-1

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  6 in total

Review 1.  The search for true numbers of neurons and glial cells in the human brain: A review of 150 years of cell counting.

Authors:  Christopher S von Bartheld; Jami Bahney; Suzana Herculano-Houzel
Journal:  J Comp Neurol       Date:  2016-06-16       Impact factor: 3.215

2.  Insulin treatment prevents diabetes-induced alterations in astrocyte glutamate uptake and GFAP content in rats at 4 and 8 weeks of diabetes duration.

Authors:  Elaine S Coleman; John C Dennis; Timothy D Braden; Robert L Judd; Phil Posner
Journal:  Brain Res       Date:  2009-10-12       Impact factor: 3.252

3.  Comprehensive behavioral analysis of patients with a major depressive episode.

Authors:  Helfried Rothuber; Bernhard Mitterauer
Journal:  Med Sci Monit       Date:  2011-05

4.  Memory in astrocytes: a hypothesis.

Authors:  Robert M Caudle
Journal:  Theor Biol Med Model       Date:  2006-01-18       Impact factor: 2.432

5.  Dexmedetomidine Attenuates Lipopolysaccharide Induced MCP-1 Expression in Primary Astrocyte.

Authors:  Huan Liu; Jacques R J Davis; Zhi-Lin Wu; Amro Faez Abdelgawad
Journal:  Biomed Res Int       Date:  2017-02-14       Impact factor: 3.411

Review 6.  Methodological limitations in determining astrocytic gene expression.

Authors:  Liang Peng; Chuang Guo; Tao Wang; Baoman Li; Li Gu; Zhanyou Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2013-11-25       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.